StockData

Lyell Immunopharma vs Senti Biosciences

LYEL and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LYEL and SNTI compare

Lyell Immunopharma is the larger company, worth 85 times as much as Senti Biosciences ($359M against $4.2M).

Lyell Immunopharma scores higher on the StockData Score (6 against 4 for Senti Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLYELSNTI
Size and price
Market cap$359M$4.2M
Share price$14.65$0.136
Change, 1 year−15.9%−92.4%
Change, 5 years−92.1%−99.9%
Beta (5Y)1.272.77
StockData Score
Total score6 (better)4
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S13296×–
P/B1.5×–
FCF yield−37.3%–
Growth
Revenue growth (TTM)−55.0%–
Revenue growth, 5Y average−65.9%–
Profitability
Operating margin−949981%–
Net margin−920285%–
FCF margin−496189%–
Return on equity−93.3% (better)−466%
Return on invested capital−782%–
Financial health
Debt / equity0.00–
Current ratio5.36 (better)0.83
Altman Z-score−6.86 (better)−21.36
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions48.9%18.6%
Held by insiders45.0%–
Insider net buying, 12 months$74.4M–
Short interest, % of float10.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.